hscgb | Health Services Charitable Gifts Board

Year End Highlights 2022-23

Funds Applied

During the year ended 30 June 2023 the Board approved Public Health Entity (PHE) budget requests of $16.4M, against which $7.04M was spent by PHEs. This was advanced for various purposes such as:

- Equipment (research and non-research);
- Research and PHE-staff Professional Development;
- Conferences and Training; and
- Other expenditure such as Volunteer support.

More details of expenditure funded can be found in pages 25-26 of the 2022-23 HSCGB Annual Report.

Highlights of Funds Applied

Set out on pages 32-35 of the HSCGB Annual Report are some of the projects and programs that have been funded in 2022-23. Examples of the research being funded includes the following:

- Cultural Immersion Project aimed at addressing cultural concerns from patients who may feel disconnected from their home, country and culture when undergoing various medical treatments which keep them away from home, family, and friends for extended periods of time. The aim is to support healing, cultural connection and improve general wellbeing.
- Telemedicine Implementation project run through Women's and Children's Hospital now in its third year of funding and continuing to improve access to healthcare services for patients who live in regional, rural, and remote areas.
- One of the CEO Rapid Improvement Project Scheme (CRIPS) projects funded at the RAH through 2022-23 was Improving Care pathways through Tertiary and Primary Service Integration. This project set out to understand and define healthcare experiences for patients commencing chronic dialysis (particularly the interface between primary and tertiary healthcare systems) and to develop, implement and evaluate strategies to improve primary care and support for those patients based on the identified experiences.

During 2022-23, RAH again requested significant funding for a Da Vinci XI Robotic Assisted Surgical System. The Da Vinci XI System provides world class minimally invasive robotic assisted surgery in cancer and other fields. Although ultimately not purchased in the 2021-22 or 2022-23 financial years, funding for the Da Vinci XI System has again been committed to be provided during 2023-24.

The list of projects funded during the 2022-23 financial year is extensive. Detailed below are some of the projects where significant funds were advanced during the year.

- Research and Research Equipment.
- (CRIPS) Reducing unplanned chronic dialysis start – implementing pathways for integrated tertiary and primary care of advanced chronic kidney disease (CKD).
- (CRIPS) The impact of an emergency department protocol and rapid access AF clinic to reduce hospitalisations for atrial fibrillation (REDUCE AF).
- (CRIPS) Aboriginal dialysis models of care – improving health outcomes in Aboriginal patients by improving adherence to dialysis treatment.
- (CRIPS) Advanced Recovery Room Care – an iterative model to improve outcomes and reduce cost in perioperative care.

- SA Cancer Research Biobank – contribution towards ensuring maintenance of the Biobank which provides tumour tissue samples for medical research to improve patient outcomes.
- Elucidating coding region targets of micro RNAs.
- Does resection of metastatic lateral lymph nodes in patients with rectal cancer improve survival?
- Funding of research equipment including Zeiss Axioscan with brightfield and fluorescence scanning. Quantstudio 7 flex 384 well-fixed block PCR with additional capacity for protein thermostability measurement.; Nova Flex2 Bioprofile Analyser; 500 watt Ultrasonic Processor. Refrigerated benchtop Centrifuge 5810/5810 R (15ml and 50ml tubes).

Ray and Shirl Norman Cancer Research Trust (Norman Trust)

During 2022-23, funding of $0.47m was applied to the following multi-year research projects funded through the Norman Trust of which the Board is Trustee:

- BCR-ABL1 independent genomic factors that influence treatment decisions and outcome for patients with chronic myeloid leukaemia.
- Assessing novel therapeutics for the treatment of chemotherapy-resistant ovarian cancer.
- Can senolytic agents, which target senescent bone marrow mesenchymal stromal cells, inhibit the progression of multiple myeloma?
- Development of new combination immunotherapies for glioblastoma based on Chimeric Antigen Receptor (CAR)-T cell and Bispecific T cell Engager (BiTE) technologies.

From late 2018 through to early 2021, the Norman Trust also funded (among two others) a project run by Professor Simon Conn “Circular RNAs as trojan horses of oncogenesis”. Recently the continuing success of this project has led to Professor Conn publishing further discovery in a world-leading journal. In Professor Conn’s words:

> *“I was humbled to have received funding from the Ray & Shirl Norman Cancer Research Trust. This supported our research into the formation of mutations which drive a devastating form of blood cancer, called acute myeloid leukemia. While we have long understood that external factors such as diet, ultraviolet light, smoking or genetic factors that are inherited from your parents, this research identified internal genetic fragments are able to drive the cancer-causing mutations. This discovery, published in the world-leading journal Cancer Cell, is rewriting the textbooks regarding the understanding of how cancers can arise. As a result, this work was the subject of over 100 news articles across the world and has resulted in me being invited to give plenary seminars at conferences in China, Greece, New Zealand and USA. I would like to thank the HSCGB for trusting me with these funds and sincerely believe these have been gainfully employed to achieve publications and also large funding through the National Health and Medical Research Council.”*

Income

Total income for 2022-23 was $17.53M. The increase was attributable to significantly stronger investment performance than the preceding year which offset the lower level of gifts received.

Of the $7.04M received in Bequests and other Gifts and Donations:

- 34% was received for RAH and TQEH;
- 39% for WCHN;
- 22% for SA Pathology and Hanson Centre; and
- 5% across the other PHEs.

Investments

The investment performance for the portfolios under management for the Board was as follows:

Portfolio	1 yr % pa return	3 yr % pa return	7 yr % pa return
HSCGB Pool	2.5%	2.1%	3.0%
The Ray & Shirl Norman Cancer Research Trust	3.3%	2.0%	4.1%
DE Brown Charitable Trust	6.0%	3.2%	4.1%
PF Beinke (RAH)	6.0%	3.2%	**n/a
PF Beinke (FMC)	6.0%	3.2%	**n/a
PF Beinke (RAH)	6.0%	3.2%	**n/a

More details of income for the year can be found in pages 16-17 of the 2022-23 HSCGB Annual Report.

At 30 June 2023, a total of $172.68M was held by the Board. Of this sum 83% was held on behalf of the RAH and TQEH. More details can be found at Note 10 of the financial statements as contained in the 2022-23 HSCGB Annual Report.

The activities of the Board are audited by the Auditor-General. His report can be found at page 45 of the 2022-23 HSCGB Annual Report.